ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
SCYNEXIS Announces Positive Results of Oral Ibrexafungerp to Treat Severe Fungal Infections
March 05, 2021SCYNEXIS announced positive results from the third interim efficacy analysis of the ongoing open-label Phase 3 FURI study and the first interim analysis of the ongoing open-label Phase 3 CARES study. -
SCYNEXIS Announces Positive Results from Ibrexafungerp Study
January 13, 2020SCYNEXIS announced positive results from its second interim efficacy analysis of the ongoing Phase 3 open-label FURI study. The study is evaluating oral ibrexafungerp as a salvage treatment in patients with difficult-to-treat mucocutaneous and ...
Pharma Sources Insight January 2025
